On September 8, 2021 SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human polyclonal antibodies without the need for human donors, reported that Eddie J. Sullivan, PhD, co-founder, president and CEO, will present at two upcoming virtual investor conferences in Septembe (Press release, SAB Biotherapeutics, SEP 8, 2021, View Source [SID1234587426])r. Presentation details can be found below:
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
H.C. Wainwright 23rd Annual Global Investment Conference.
Format: Pre-recorded presentation available for on-demand viewing
Date/Time: Monday, September 13 at 7:00 a.m. ET through Sunday, December 12 at 7:00 a.m. ET
Registration Link
Baird Global Healthcare Conference
Format: Fireside chat
Date/Time: Tuesday, September 14 at 12:50 p.m. ET
Registration Link
An on-demand webcast of the H.C. Wainwright presentation and archived replay of the Baird fireside chat will be accessible through the "News" section of the company’s website at www.sabbiotherapeutics.com
On June 22, 2021, SAB announced a planned merger with Big Cypress Acquisition Corp. (NASDAQ: BCYP). The transaction is expected to close in the fourth quarter of 2021.